<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/53A8F4B4-EBD0-4199-B24B-B5008112311D"><gtr:id>53A8F4B4-EBD0-4199-B24B-B5008112311D</gtr:id><gtr:name>Guy's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/11BA9F46-16B8-4410-A960-2C402F3AC5B0"><gtr:id>11BA9F46-16B8-4410-A960-2C402F3AC5B0</gtr:id><gtr:name>Mauna Kea Technologies</gtr:name><gtr:address><gtr:line1>9, rue d'Enghien</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/93B13D3A-863C-46E8-A4C7-1EE4759A7E9B"><gtr:id>93B13D3A-863C-46E8-A4C7-1EE4759A7E9B</gtr:id><gtr:name>Cleveland Clinic</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/53A8F4B4-EBD0-4199-B24B-B5008112311D"><gtr:id>53A8F4B4-EBD0-4199-B24B-B5008112311D</gtr:id><gtr:name>Guy's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11BA9F46-16B8-4410-A960-2C402F3AC5B0"><gtr:id>11BA9F46-16B8-4410-A960-2C402F3AC5B0</gtr:id><gtr:name>Mauna Kea Technologies</gtr:name><gtr:address><gtr:line1>9, rue d'Enghien</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/93B13D3A-863C-46E8-A4C7-1EE4759A7E9B"><gtr:id>93B13D3A-863C-46E8-A4C7-1EE4759A7E9B</gtr:id><gtr:name>Cleveland Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7B2AAAF1-367B-4FB9-B147-F169B0B84A26"><gtr:id>7B2AAAF1-367B-4FB9-B147-F169B0B84A26</gtr:id><gtr:firstName>Bruce</gtr:firstName><gtr:otherNames>C</gtr:otherNames><gtr:surname>McGorum</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/670260BC-6C2F-4969-AC3A-605AC2879977"><gtr:id>670260BC-6C2F-4969-AC3A-605AC2879977</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Haslett</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0F243FCD-57DA-48E3-9933-8193EA373C82"><gtr:id>0F243FCD-57DA-48E3-9933-8193EA373C82</gtr:id><gtr:firstName>Nik</gtr:firstName><gtr:surname>Hirani</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/136DED6D-E7F0-4C3D-AF00-E7FECA1DFB63"><gtr:id>136DED6D-E7F0-4C3D-AF00-E7FECA1DFB63</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Bradley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/36B6C31F-AEF8-46B4-A57A-EE690EC04394"><gtr:id>36B6C31F-AEF8-46B4-A57A-EE690EC04394</gtr:id><gtr:firstName>Kev</gtr:firstName><gtr:surname>Dhaliwal</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ014702%2F1"><gtr:id>F8BDDAB5-746A-4DC9-96E2-B56708ECC505</gtr:id><gtr:title>Molecular Optical Imaging of Key Targets in the Fibrogenic Pathway in Man</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J014702/1</gtr:grantReference><gtr:abstractText>Fibrosis, or scarring, is a process which complicates many diseases of the lung and other organs and for which no effective treatment is available. There are currently no ways to detect the activity of fibrosis in human tissues in life.

The ability to specifically monitor fibrosis non-invasively in diseased organs would enable stratification of disease and to personalise treatment as well as facilitate the rapid design and testing of new drugs in patients with 'real disease' without the need for animal experimentation.

This project aims to develop 'smart' probes to detect fibrosis in 'real time' in human tissues. This is achieved by the combined application of 'cutting-edge' technology to perform optical imaging microscopy deep in diseased organs to detect the activity of a tiny dose of a coloured compound which has been designed to specifically detect key events in the fibrotic process. This 'microdose' involves no toxicity or radiation exposure.
 
This technology will enable us not only to detect fibrosis and develop new drugs for human disease but will also be applicable to scarring diseases in animals. Thus the proposed studies using tissue from donkeys, which have a very high natural incidence of a form of lung scarring which is virtually identical to the human variety, will not only help our human translational pathway, but will also provide the basis of much-needed treatment for sick animals.</gtr:abstractText><gtr:technicalSummary>Fibrotic diseases of the lung and other organs constitute a heavy burden of morbidity and untimely deaths. Idiopathic Pulmonary Fibrosis (IPF) is diagnosed late (on CT scans/lung biopsy) and has an appalling mortality. It is currently impossible to identify patients with Adult Respiratory Distress Syndrome (ARDS) and other inflammatory lung diseases that are developing secondary fibrosis. Moreover there are no effective therapies for fibrosis despite it being a highly active cellular process which should be accessible to intervention. Part of the problem has been the time required to establish drug effectiveness in vivo and the poor utility of existing biomarkers. The innovative translational pathway detailed herein will create novel active markers of fibrogenesis in situ to rapidly establish early diagnosis and efficacy of much needed new therapies in scarring diseases of the lung and other organs. Supported by a previous MRC 'devolved' DPFS award our team has already synthesised a highly-specific human neutrophil smartprobe which has been validated exhaustively in vitro and in vivo using pCLE and is now in GMP synthesis for human application. From this strong foundation we are confident of achieving the aims of the current application.
KEY GOALS:
1) To allow clinicians to rapidly and accurately determine the presence of active fibroproliferation.
2) To apply cutting-edge bronchoscopic confocal imaging technology (pCLE) partnered with local instillation of highly specific and sensitive 'smart' molecular probes at microdose concentrations (&amp;lt;100 mcg).
3) To generate a novel portfolio of GMP-grade materials for first-in-man validation studies that are commercially valuable.
4) To develop potentially gold-standard methodologies for rapidly assessing the efficacy of new antifibrotic drugs in clinical trials and for patient stratification.

This strategy will accelerate the pharmaceutical development and clinical application of antifibrotics.</gtr:technicalSummary><gtr:potentialImpactText>Impacts on patients and patient pathways: 
Rapid and accurate bedside testing for pulmonary inflammation/fibrosis is a &amp;quot;holy grail&amp;quot; in modern respiratory medicine. Currently clinicians are faced with significant uncertainty in relation to assessing pulmonary fibrosis and evaluating disease activity. Better characterisation of pulmonary fibrosis in real-time provides the potential to target existing and novel therapies and detect early predictors of clinical response. For example, despite negative clinical trials, steroids are still widely used in pulmonary fibrosis. Smartprobes offer the potential to improve the risk/benefit profile of steroid therapy and other existing and new therapies by enabling disease-specific effects to be measured rapidly in the individual patient This has the potential to improve patient health while reducing costs. 

Exploitation and Application: 
This DPFS programme will deliver vital under-pinning biology and chemistry to help address major medical needs/problems in an international setting. We will explore all avenues for the benefit of the UK's economic competitiveness as we believe the research undertaken is likely to generate new concepts, ideas and research tools. Importantly all applicants have a history of patent protecting appropriate discoveries, working with industry and capitalising on discoveries that have had a positive impact on business. The team established thus understands the importance of IP and its appropriate protection but also realises that specialised assistance (through the University of Edinburgh Research and Innovations office) is necessary in order to evaluate, develop and exploit novel IP arising from the research activities. Indeed the close relationship between the Bradley &amp;amp; Haslett groups with Edinburgh Research and Innovation (ERI) (which seeks to promote the University of Edinburgh's research and commercialisation activities) will allow all commercialisation routes to be explored in a responsive and dynamic manner.

Wealth creation for the public:
The teams view is that spinout is a realistic option and has the greatest potential to develop these probes (and in the longer-term additional probes) providing services, probes for preclinical validation, collaborative R&amp;amp;D, but most importantly clinical probes. The Edinburgh BioQuarter is an ideal site for the new company venture as it is adjacent to the hospital and it has recently appointed Dr Capaldi as the new director whose singular purpose is to support company formation. The team also have a strong pedigree in this area, thus Professor Bradley has been involved with a number of spinouts. This includes co-founder of Ilika Technologies (2004)(floated on the London Stock Exchange 2010), Altrika Technologies (2009) and Deliverics (2010). Professor Bradley is an inventor on some 15 patents with a strong record of exploiting IP. Professor Haslett was the first to recognise the translational opportunities offered by PET imaging of FDG as well as F-18 cis-proline in man as well as being the inventor on the UoE patent based on the use of Roscovitine in inflammation.

Research Partnership: 
This is clearly a multi-disciplinary activity, requiring the creation of a team of researchers with the necessary expertise and experience in their individual disciplines to realise the opportunities and address the challenges. The University of Edinburgh will benefit from the creation of such a team in terms of their international standing, building of interdisciplinary links, and their ability to attract future funding and industrial support.

Developing Entrepreneurship: 
Many optional training opportunities will be available to the scientists through existing mechanisms. The Scottish Institute for Enterprise provides training and support in entrepreneurship and business skills. This is in line with the objectives of the RCUK to develop entrepreneurship within the academic culture and the development of enterprise skills</gtr:potentialImpactText><gtr:fund><gtr:end>2015-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>806826</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCB Celltech</gtr:department><gtr:description>Pharmaceutical Industry</gtr:description><gtr:id>0AA03635-3DE9-49AA-8548-8F0FD468A18E</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>56db5f8f9ef769.98038105-1</gtr:outcomeId><gtr:partnerContribution>Providing descriptions of development pathways</gtr:partnerContribution><gtr:piContribution>Providing samples and reagents</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mauna Kea Technologies</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Mauna Kea Technologies</gtr:description><gtr:id>5934F700-EB7C-4EC0-A57F-A50F4911EA3D</gtr:id><gtr:impact>Development and delivery of 40 clinical catheters to our group.</gtr:impact><gtr:outcomeId>56dc1ff8a31761.30614371-1</gtr:outcomeId><gtr:partnerContribution>Manufacture, quality management systems , sterility validation</gtr:partnerContribution><gtr:piContribution>Developing a delivery catheter to deliver optical imaging agents to the distal lung. We tested prototypes, contributed to the risk assessment and also are performing the initial clinical trials of the catheter</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cleveland Clinic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Cleveland Clinic</gtr:description><gtr:id>B94859CD-64EA-4ECD-8809-7813C07A1F97</gtr:id><gtr:impact>The Cleveland Clinic has successfully received an eIND from the FDA to perform clinical studies using imaging agents that have been developed by the team at Edinburgh.</gtr:impact><gtr:outcomeId>56dc1e68346a67.64903033-1</gtr:outcomeId><gtr:partnerContribution>Access to patients and clinical network input to initiate clinical trials.</gtr:partnerContribution><gtr:piContribution>Developing a collaborative partnership to expedite the implementation of optical molecular imaging in the USA and in particular in respiratory medicine. Exchanging ideas, projects and clinical protocols for the Cleveland Clinic to begin initiating an optical imaging programme in Respiratory Medicine using imaging agents developed in Edinburgh</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Guys</gtr:description><gtr:id>E6CDCDAE-2208-40C1-A7C1-E583E24F4A9F</gtr:id><gtr:impact>Successful GMP manufacture of optical imaging agents for clinical trials</gtr:impact><gtr:outcomeId>56dc2408cc6371.56258403-1</gtr:outcomeId><gtr:partnerContribution>Providing academic rates for sterile fill GMP production so that we can complete clinical studies</gtr:partnerContribution><gtr:piContribution>Developing a sterile fill collaboration with the Guys NIHR facility</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>11600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>IRC award (Bradley/Dhaliwal/Haslett)</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/K03197x/1</gtr:fundingRef><gtr:id>CF238DB1-1E70-4B71-B14F-054A6703FEBD</gtr:id><gtr:outcomeId>QvF2X5UoE9j</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The FIB ONE compound is based on an Aminomethyl Chemmatrix resin linked to three 5- carboxyfluorescein (FAM) molecules via a Rink Amide linker. The FAM molecules are bonded to three quenchers (Methylred) by a peptide sequence acting as substrate for the target enzyme (MMP 2/9/13). In the inactive state, the emission from the fluorophore moiety is absorbed by the quencher by F&amp;ouml;rster Resonance Energy Transfer (FRET), but in the presence of the target enzyme this can cleave the substrate disrupting the FRET and causing a rapid increase in fluorescence.

We have obtained all of the relevant approvals to run our proof of concept study and it is thought that this will begin in March 2016. All updates on this have been provided in the end of project report.</gtr:description><gtr:id>EFBB6F0C-1568-4C43-A970-4DFB6CDDDF70</gtr:id><gtr:impact>The development of FIB ONE will be used to develop a novel approach to address the unmet needs of identifying and measuring the pulmonary fibroproliferative pathway.</gtr:impact><gtr:outcomeId>56cc5bf8845f86.88785202</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>FIB ONE</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>This device was developed with Mauna Kea Technologies as part of a MICA award from the DCS award. The catheter has gone through extensive testing and has now been delivered to Edinburgh for clinical testing. It is a unique triple lumen catheter that is less than 1.7 mm in diameter and can access the working channel of the bronchoscope.</gtr:description><gtr:id>1B0DAABA-C41C-49E6-BEA6-0C9697B62DEF</gtr:id><gtr:impact>New collaboration with the University of Utah - Professor Bob Hitchcock. Dept of Engineering. 
Novel applications have led to GSK being interested in using the device for pulmonary drug deposition studies and a GSK investigator led study is now being planned.</gtr:impact><gtr:outcomeId>56dc219a4579d4.13306615</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Triple Lumen Bronchoscopic Delivery Device</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Novel method of measuring MMP activity</gtr:description><gtr:id>D214B67E-46DE-46BA-B9AE-34809CEF230E</gtr:id><gtr:impact>Novel method of sensing MMP activity in human tissue</gtr:impact><gtr:outcomeId>56db600a490547.70822608</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MMP sensing</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Edinburgh Molecular Imaging</gtr:companyName><gtr:description>SME that is focussing on Optical Molecular Imaging and the rapid commercialisation of in vivo optical imaging agents for human disease</gtr:description><gtr:id>0E768A00-3FD4-4352-8903-D19CED58FE5D</gtr:id><gtr:impact>Raised &amp;pound;4M Series A. Awarded Innovate UK award.</gtr:impact><gtr:outcomeId>56db533dd03a98.30306163</gtr:outcomeId><gtr:url>http://www.edinimage.com</gtr:url><gtr:yearCompanyFormed>2014</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>19D06787-1454-4EA3-AC66-299A04FE2CDA</gtr:id><gtr:title>Chronic pleuropulmonary fibrosis and elastosis of aged donkeys: similarities to human pleuroparenchymal fibroelastosis.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/242ca647774fd562bbf7eeee264241fa"><gtr:id>242ca647774fd562bbf7eeee264241fa</gtr:id><gtr:otherNames>Miele A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>543fb922a8e670.63125798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8BC52A7-D324-4C5A-9389-CD3BC04839E5</gtr:id><gtr:title>Highly specific, multi-branched fluorescent reporters for analysis of human neutrophil elastase.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18f288c92165e764eefc2343660d3bdc"><gtr:id>18f288c92165e764eefc2343660d3bdc</gtr:id><gtr:otherNames>Avlonitis N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>pm_16194_24_23715090</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DE2A4B5-5823-4F31-A4C3-F67942B82452</gtr:id><gtr:title>Optical molecular imaging of lysyl oxidase activity - detection of active fibrogenesis in human lung tissue</gtr:title><gtr:parentPublicationTitle>Chemical Science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a8b81f64ab78d3fbef83140c886518a"><gtr:id>0a8b81f64ab78d3fbef83140c886518a</gtr:id><gtr:otherNames>Aslam T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>58c00f17977816.54589243</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C3D637D-2691-4FA4-9BC6-B2D5C14703DA</gtr:id><gtr:title>Combined dysfunctions of immune cells predict nosocomial infection in critically ill patients.</gtr:title><gtr:parentPublicationTitle>British journal of anaesthesia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d7f730c06e18455fc8fcea0cdb66c2d"><gtr:id>6d7f730c06e18455fc8fcea0cdb66c2d</gtr:id><gtr:otherNames>Conway Morris A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0912</gtr:issn><gtr:outcomeId>pm_16194_24_23756248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F681FEE-470F-4E8F-A5CB-FE2DEE42C116</gtr:id><gtr:title>Constitutive apoptosis in equine peripheral blood neutrophils in vitro.</gtr:title><gtr:parentPublicationTitle>Veterinary journal (London, England : 1997)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3567e6e30e75e66d876bbcc1d567548"><gtr:id>d3567e6e30e75e66d876bbcc1d567548</gtr:id><gtr:otherNames>Brazil TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1090-0233</gtr:issn><gtr:outcomeId>5458a78612cb37.17377097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>588674F7-A264-4F24-B9FE-56454E5D30BA</gtr:id><gtr:title>Highly selective and rapidly activatable fluorogenic Thrombin sensors and application in human lung tissue.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94f355e917ebd20f7967e877604074cd"><gtr:id>94f355e917ebd20f7967e877604074cd</gtr:id><gtr:otherNames>Megia-Fernandez A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>5a73216acab369.48544330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8C76094-0C84-406C-9656-1187F516B307</gtr:id><gtr:title>Wogonin induces eosinophil apoptosis and attenuates allergic airway inflammation.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5aeb0c67fdf9cb4756bd82fe23617d8f"><gtr:id>5aeb0c67fdf9cb4756bd82fe23617d8f</gtr:id><gtr:otherNames>Lucas CD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c00db016aff7.66333680</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63F7CAB5-CB13-40B6-96A7-C556B98BFADB</gtr:id><gtr:title>The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/994f32bbf7680bf25a2c8c6d4d577a6e"><gtr:id>994f32bbf7680bf25a2c8c6d4d577a6e</gtr:id><gtr:otherNames>Dorward DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>58c00dafdd9bb7.56301710</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EBD6169-2E89-4C01-A820-AFC764072289</gtr:id><gtr:title>Surface-enhanced Raman scattering in cancer detection and imaging.</gtr:title><gtr:parentPublicationTitle>Trends in biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6d51c11279fc76c6170807af338f5d8"><gtr:id>f6d51c11279fc76c6170807af338f5d8</gtr:id><gtr:otherNames>Vendrell M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0167-7799</gtr:issn><gtr:outcomeId>pm_16194_24_23416096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAFDD125-0B5F-4449-8418-287ABE8C9264</gtr:id><gtr:title>Technical advance: autofluorescence-based sorting: rapid and nonperturbing isolation of ultrapure neutrophils to determine cytokine production.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/994f32bbf7680bf25a2c8c6d4d577a6e"><gtr:id>994f32bbf7680bf25a2c8c6d4d577a6e</gtr:id><gtr:otherNames>Dorward DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>pm_16194_24_23667167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8571BE0-4C5A-43E7-9F97-06DA2808A537</gtr:id><gtr:title>A randomized controlled trial of peripheral blood mononuclear cell depletion in experimental human lung inflammation.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc797cd3a172aa8fe324b25328d15fb5"><gtr:id>dc797cd3a172aa8fe324b25328d15fb5</gtr:id><gtr:otherNames>Barr LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_16194_24_23627345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5ADA1A21-E06B-486F-BCCF-20089D3333BE</gtr:id><gtr:title>In-situ imaging of neutrophil activation in the human alveolar space with neutrophil activation probe and pulmonary optical endomicroscopy</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5418ba6c03b1d7d2cfbf4bc37f74d0b"><gtr:id>f5418ba6c03b1d7d2cfbf4bc37f74d0b</gtr:id><gtr:otherNames>Craven T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>56db51dc51bb97.83819207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>287D4110-E068-4FC3-85C5-C932BFAD9765</gtr:id><gtr:title>Genetic and pharmacological inhibition of CDK9 drives neutrophil apoptosis to resolve inflammation in zebrafish in vivo.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e37c74cabd9fe17a83cfb20d2bd4f3e5"><gtr:id>e37c74cabd9fe17a83cfb20d2bd4f3e5</gtr:id><gtr:otherNames>Hoodless LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58c00dafaf0336.84297112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A39FD43C-59A9-4E7A-A822-6BC0ACA86316</gtr:id><gtr:title>The cyclin-dependent kinase inhibitor AT7519 accelerates neutrophil apoptosis in sepsis-related acute respiratory distress syndrome.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/994f32bbf7680bf25a2c8c6d4d577a6e"><gtr:id>994f32bbf7680bf25a2c8c6d4d577a6e</gtr:id><gtr:otherNames>Dorward DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>58c00daf7b3f69.06982326</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J014702/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>